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In an open-label, prospective non-randomized cohort study, we compared the effectiveness and
tolerability profiles of the homeopathic remedy Nervoheel N with those of the benzodiazepine,
lorazepam, in 248 patients with insomnia, distress, anxieties, restlessness or burnout and similar
nervous conditions (‘mild nervous disorders’). Patients were treated with Nervoheel N or
lorazepam at the recommended doses for a maximum of 4 weeks. Dose variations were allowed
if in the patient’s best interest. Treatment effects were evaluated by the practitioner in a
dialogue with the patient at the start of treatment, after 2 weeks and after maximally 4 weeks of
treatment. Tolerability data were recorded as adverse events. At baseline, lorazepam patients
were on average slightly older and there was a somewhat greater percentage of men in this
group than in the Nervoheel group. Both treatment groups reported significant symptomatic
improvements of similar magnitude during the course of the study. The sum of symptom scores
improved by 4.4 points with Nervoheel N and by 4.2 points with lorazepam. The differences
between the treatment groups were not significant. All differences between treatments were
within 10% of the maximum score ranges, demonstrating non-inferiority of Nervoheel N. Both
treatments were well tolerated, with few adverse events and very good self-assessed tolerability
ratings by the patients. Thus, in patients who opt for a homeopathic treatment regimen for the
short-term relief of mild nervous disorders, the effects of Nervoheel N are non-inferior to those
of lorazepam.
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Introduction
Medical therapy with pharmacological agents is to a large
extent a trade-off between the dose-related therapeutic
efficacy of the drug and its likewise dose-related side
effects. Throughout the last century, the terms of this
trade-off have become increasingly favorable, as treat-
ments have become better tolerated. However, conven-
tional medical pharmacotherapies are unlikely to be
entirely free from unwanted effects. Indeed, the last few
years have seen well-publicized instances of drugs being
withdrawn from the market because of side effects that
might have been acceptable in earlier eras of medicine,
most recently cerivastatin and rofecoxib. Such disen-
chantment with medications are among the reasons for
the increasing use of complementary and alternative
medicine (CAM) (1), an area where medications are
perceived as better tolerated than conventional drugs (2).
Among the areas where CAM is frequently used is for
the symptomatic treatment of insomnia, distress, anxi-
eties, restlessness, burnout and similar nervous condi-
tions, all of which are common in the general population.
Successful use of transcendental meditation for the relief
of post-traumatic stress disorder was reported recently (3)
and homeopathic preparations based on highly diluted
extracts from flavonoid-rich plants are applied to a
variety of nervous conditions (4). This complex nature of
nervous disorders is reflected in a complexity of
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properly cited.treatments and medications, including a high degree of
self-medication, ranging from alcohol to herbal remedies
(5,6). The reluctance to seek conventional medical help
and the wide use of CAM practices may indicate a
perception of risk associated with pharmacotherapies.
Also, commonly prescribed treatments such as benzodia-
zepines are contraindicated for long-term use, because of
their addictiveness and side effects, including residual
daytime sedation (‘hangover’), anterograde amnesia and
respiratory depression (7). Benzodiazepines have been
frequently implicated in drug-associated hospital admis-
sions (8). Furthermore, they may cause significant
impairment to driving and psychomotor abilities, even
at low doses (9).
There is clearly a need for a wider palette of mild
sedatives with improved tolerability profiles. From the
earlier considerations, it follows that the treatment of
mild nervous disorders is a complex matter which needs a
close interaction between patient and practitioner and a
wide variety of therapeutic options. The increased
availability of CAM practices has expanded the range
of choices for patients and practitioners beyond that of
conventional medicine. For example, in the UK, one in
10 of the adult population consults a CAM practitioner
every year (10). However, this growing role of CAM
increases the need for assessments of the effectiveness and
tolerability of medications used. A lack of controlled
clinical studies on many alternative medications means
that practitioners and patients have to rely on anecdotal
evidence under inadequately controlled conditions (11).
Nervoheel N (Heel GmbH, Baden-Baden Germany) is
a preparation based on the principles of homotoxicology.
This uses combinations of ingredients at lower potencies
than in classical homeopathy and therapy is more
indication-based and less individualized than homeo-
pathic therapies.
Nervoheel N is indicated for the temporary relief of
symptoms of stress, including restlessness, insomnia,
nervous tension and stress due to premenstrual syndrome
and menopause, as well as restlessness in children.
The regular dosage is one tablet dissolved under the
tongue three times daily. As with many homeopathic and
homotoxicological preparations, the range of symptoms
for which Nervoheel N is used in daily practice is wide
and includes nervous overstrain, minor exogenic depres-
sions and insomnia. The components of Nervoheel N,
listed in Table 1, are of mineral origin (phosphoric acid;
potassium bromide), in combination with extracts from
the medicinal plant Strychnos ignatii (St. Ignatius’ Beans)
valerinate of zinc and Sepia officinalis (cuttlefish extract).
All are used at the dilution D4, lesser dilutions than those
used in homeopathic medications.
As with most CAM medications, there are few data on
Nervoheel N from clinical trials and its wide use is based
on clinicians’ and patients’ personal good experience with
the preparation more than evidence from controlled
trials. To obtain more information on the effectiveness
of Nervoheel N in routine CAM practice, we compared,
in an open-label observational study, the effectiveness
and tolerability profiles of Nervoheel N with those of the
benzodiazepine, lorazepam, in 248 patients with mild
complaints of nervous origin such as: aches, palpitations,
indigestion, lack of appetite, mild sexual dysfunction,
fatigue, listlessness, sleep disturbances, restlessness, or
lack of concentration. Lorazepam is manufactured under
a variety of trade names; the one used in the current
study (Temesta; Wyeth) is available in many European
countries. In the United States, two commonly prescribed
brands are Loraz (Quantum) and Ativan (Biovail).
Lorazepam has a relatively short half-life and is favored
over long-acting benzodiazepines such as clonazepam or
diazepam for the short-term relief of manifestations of
excessive anxiety in patients with anxiety neurosis (12).
Methods
Study Design
This was an open-label, prospective non-randomized
cohort study conducted in 39 centers in Belgium and
the Netherlands. Participating centers included practices
offering both conventional therapy and CAM practices.
The targeted total enrollment was 240 patients,
Table 1. Composition of Nervoheel N
Component Dilution Amount per
tablet mg
Homeopathic indications
Acidum phosphoricum
(phosporic acid)
D 4 60.0 Physical and mental exhaustion, deficiency of memory,
debilitating hyperhidrosis
Kalium bromatum
(potassium bromide)
D 4 30.0 Restless hands, amnesia, speech disorders
Zincum valerianicum
(valerinate of zinc)
D4 30.0 Nervous insomnia, restlessness, ‘motorist’s legs’, restless legs
Strychnos ignatii
(St. Ignatius’ Beans)
D 4 60.0 Exogenic depression, tendency to weep,
lability of mood, globus hystericus, migraine
Sepia officinalis
(cuttlefish extract)
D 4 60.0 Lassitude, nervous exhaustion, depression, climacteric neurosis
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about the background and purpose of the study, which
was conducted in full compliance with the principles of
the Declaration of Helsinki (13) and with the German
recommendations for the planning, execution and evalua-
tion of observational studies (Bundesanzeiger Federal
Gazette No. 299 of December 4, 1998).
Entry criteria were age 18 years and the presence of
one or more of the following: headache, heart palpita-
tions, backache, indigestion, lack of appetite, mild sexual
dysfunction, fatigue, listlessness, sleep disturbances,
restlessness, or lack of concentration. Excluded were
patients unable or unwilling to participate and patients
taking both study medications.
Treatments
Three patients at each center were to receive Nervoheel
N and three lorazepam (Wyeth, The Netherlands) for
a maximum of 4 weeks. The choice of treatment in each
individual case was at the physician’s discretion, based on
their judgment of the most suitable treatment for each
individual patient. As is common in homeopathy and
homotoxicology, the patients were expected to participate
in the decision after discussions with the physician.
Any other therapeutic regimen was to be unchanged
during the course of the trial, unless mandated by a
change in the status of the patient. Nervoheel N was
given at the regular dose, which is one tablet dissolved
under the tongue three times daily. Lorazepam was
administered in the form of tablets at the recommended
dose of 2–3mg/day for sedation and anxiety and 2–4mg
taken at bedtime for insomnia. Variations from the
recommended dosages were allowed if this was consid-
ered to be in the patient’s best interest.
Evaluations
Treatment effects were evaluated by the practitioner in
a dialogue with the patient. Evaluations were carried out
at the start of treatment, after 2 weeks and after
maximally 4 weeks of treatment. Severity of symptoms
was evaluated on a four-point scale where 0 indicates
asymptomatic; 1 mild, 2 moderate and 3 severe symp-
toms. In addition to the individual variables, the
summary score of all variables was calculated. Further,
an assessment of the overall effects of the therapies was
done by the physician in a dialogue with the patient,
evaluating the therapeutic results on a five-point scale
ranging from excellent, good, satisfactory, no improve-
ment to worsening of symptoms).
Tolerability data were recorded as patient-reported
adverse events evaluated by the physician. In addition,
the overall tolerability of the treatment regimens were
assessed by the physician in dialogue with the patient
as excellent, good, moderate or poor. Compliance was
rated by the physician based on discussions with the
patients on a similar rating scale from excellent, good,
moderate to poor.
Statistical Analyses
All efficacy criteria were evaluated by summary statistics
by treatment group using absolute and relative numbers
of symptom scores at entry, at the intermediate and at
the final examination. For all symptom scores arithmetic
means, standard deviation, median, minimum, maximum,
1st quartile and 3rd quartile were calculated. Between-
groups differences were evaluated with the Cochran–
Mantel–Haenszel test. Statistical comparisons were
conducted with ANOVA and Fischer’s exact test as
appropriate. For all comparisons, differences between the
Nervoheel and the control group and its two-sided 95%
confidence limits limits were calculated from least square
means using ANOVA with factors treatment, baseline
and propensity score.
Non-inferiority was calculated based on the method of
one-sided confidence limits. A non-inferiority analysis
was carried out for: headache, heart palpitations, back-
ache, indigestion, lack of appetite, mild sexual dysfunc-
tion, fatigue, listlessness, sleep disturbances, restlessness,
lack of concentration; as well as for the summary score
of all variables. A clinically relevant non-inferiority limit
for the lower boundary of the 95% confidence interval
for the differences between the treatment groups was set
to 10% of the maximum score ranges.
As the aim of the study was to show non-inferiority of
Nervoheel N compared with Lorazepam, a per-protocol
population was used for the analysis of the effectiveness
variables. An additional intention-to-treat analysis was
performed to evaluate the robustness of the results.
To adjust for patients groups not being statistically
comparable for certain variables at baseline and to
control the influence of these criteria on the effect of
treatment for each patient, propensity scores were
estimated using logistic regression (procedure logistic
with option ‘selection=forward’ in SAS) using standard
methods (14). Propensity scores were calculated using
stepwise logistic regression based on demographics and
other baseline characteristics. Logistic regression was
performed using procedure logistic from SAS and
patients were stratified into quintiles according to
propensity score based on all baseline variables using
rank procedure.
Results
Patients
A total of 248 patients were recruited for the study.
The intent-to-treat population consisted of 136 patients
eCAM 2009;6(4) 509in the Nervoheel N group and 112 in the lorazepam
group. In the Nervoheel N group, 128 patients were
examined at the interim examination and 134 patients
were available for the final examination. For the
lorazepam group, the corresponding numbers were 106
for the interim examination and 111 for the final
examination. A total of 16 patients were excluded from
the per-protocol population for the non-inferiority
analysis: 15 because of a longer duration than 42 days
between the start of therapy and the final evaluation
and one because of premature discontinuation. Thus, the
non-inferiority analysis was carried out on 122 Nervoheel
N patients and 110 lorazepam patients, respectively.
Patients’ characteristics are shown in Table 2.
Lorazepam patients were on average older (mean 53.5
years in the lorazepam group versus 45.1 years in the
Nervoheel group) and there was a somewhat greater
percentage of men in this group. Ages in the lorazepam
group ranged from 18 to 89 years, compared with a range
from 11 (one patient) to 84 years in the Nervoheel N
group. Patients in the lorazepam group were also more
likely to smoke, and to use alcohol or coffee regularly,
Table 2. Patient characteristics at time of enrolment (ITT population). The differences between the treatmen groups were not statistically significant
Characteristic Nervoheel N
(n=136)
Lorazepam
(n=112)
P-value for difference
(after propensity-score
adjustment)
Age years 0.05
Mean (SD) 45.1 (17.3) 53.5 (16.6)
Median 44.0 54.0
1st quartile-3rd quartile 33.0–58.0 40.0–65.0
Female sex n (%) 85 (62.5%) 64 (57.1%) 0.05
Height cm (SD) 167.6 (9.2) 169.9 (8.7) 0.05
BMI kg/cm
2 (SD) 25.0 (4.4) 24.7 (4.0) 0.05
Smoker n (%) 32 (23.5%) 33 (29.5%) 0.05
Regular use of coffee n (%) 73 (53.7%) 75 (67.0%) 0.05
Regular use of alcohol n (%) 24 (17.6%) 37 (33.0%) 0.05
Most common types of nervous disorder (%)
(multiple entries possible)
0.05
Emotional distress 77 (56.6%) 61 (54.5%)
Jitteriness 76 (55.9%) 64 (57.1%)
Anxiety 53 (39.0%) 49 (43.8%)
Psychological 38 (27.9%) 33 (29.5%)
strain 34 (25.0%) 32 (28.6%)
Agitation 18 (13.2%) 14 (12.5%)
Burnout
Severity of symptoms 0.05
Mild 35 (25.7%) 17 (15.2%)
Moderate 76 (55.9%) 67 (59.8%)
Severe 23 (16.9%) 26 (23.2%)
Baseline score of variables SD 0.05
Headache 0.90.8 0.90.8
Heart palpitations 0.60.7 0.90.9
Backache 0.50.7 0.50.7
Indigestion 0.70.8 0.50.6
Lack of appetite 0.80.8 0.70.8
Mild sexual dysfunction 0.81.1 0.80.9
Fatigue 1.20.8 1.00.9
Listlessness 1.30.8 1.00.8
Sleep disturbances 1.60.9 1.70.9
Restlessness 1.20.8 1.30.9
Lack of concentration 1.30.8 1.30.9
Overall score 10.85.2 10.45.7
510 Nervoheel for mild nervous disordersthan patients in the Nervoheel N group. However, after
adjusting for propensity score, the treatment groups did
not differ at baseline on any criterion at a significance
level of 5%.
There were no significant differences between treatment
groups in distribution of nervous disorders. Only one-
third of patients in both groups presented with one single
complaint; two-thirds of patients presented with 2–4
disorders. Emotional distress, jitteriness and anxiety were
the most common complaints in both groups and 13%
in both groups suffered from burnout syndrome.
The reasons given for nervous disorders were also
highly similar: work-related anxiety, stress and family-
related anxiety made up the vast majority of complaints,
with only a low rate of illnesses such as endogenous
depression (3% in the Nervoheel N group and 5% in the
lorazepam group). The symptoms were of similar severity
in both groups, although Nervoheel N patients more
often presented with mild symptoms (25.7%) than
patients in the lorazepam group (15.2%), However,
these differences were not reflected in any differences in
the percentages of patients incapable of their ordinary
employment: 26% of Nervoheel N patients were con-
sidered unable to work compared with 28% of lorazepam
patients. Most patients were previously untreated for
their conditions: 72% of Nervoheel N patients and 74%
of those receiving lorazepam had no previous recorded
treatment.
The average treatment duration was 317 days for
Nervoheel N and 296 days for lorazepam patients.
Less than 1% of patients in both groups were treated for
<2 weeks. Although most patients (62% in the
Nervoheel N group and 70% in the lorazepam group)
chose to remain on therapy for longer than the 4 weeks’
observation period, <10% in both groups remained on
therapy for longer than 6 weeks. The use of additional
medications was low in both groups: nine patients on
Nervoheel N (6.8%) and nine patients on lorazepam
(8.1%) took any form of additional medication during
the study.
Effectiveness
The effectiveness results are given for the per-protocol
population unless otherwise indicated. There were no
notable differences between analyses of the per-protocol
population and the intent-to-treat analyses. Removing
the 11-year-old patient from the analysis did not affect
the results.
Both treatment groups reported symptomatic improve-
ment of similar magnitude during the course of the study.
The sum of symptom scores improved by 4.4 points with
Nervoheel N and by 4.2 points with lorazepam. The
differences from baseline were significant with both
treatments, but differences between the treatment
groups were not significant.
As shown in Fig. 1, most of the symptomatic
improvements were evident at the time of the inter-
mediate examination, with only minor further improve-
ments to the final evaluation. There was no clear trend
towards earlier onset of symptomatic improvement with
one treatment compared with the other: certain variables
(indigestion, mental fatigue, listlessness) tended towards
more rapid improvement with Nervoheel N and others
(heart palpitations, restlessness) towards earlier improve-
ment with lorazepam (Fig. 1). For the sum of all
symptom scores (Fig. 2), there was a trend towards
more rapid improvement with Nervoheel, but all differ-
ences were minor and there was a further improvement in
Figure 1. Changes in symptom scores from baseline to intermediate examination and to final examination, respectively. The lines indicate SEM.
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treatment groups (Fig. 2).
All changes in individual variables were highly similar
in both treatment groups. For all variables, the lower
boundary of the 95% confidence interval was greater
than 0.3, i.e. all chances were within 10% of
the maximum score ranges which demonstrated non-
inferiority of Nervoheel N (Fig. 3). For the sum of all
scores, the lower boundary of the 95% confidence
interval was 0.91, which was well within the boundaries
defining non-inferiority of Nervoheel N to lorazepam
overall.
The overall therapeutic results as evaluated by practi-
tioner and patient corresponded to those for the
individual components and the summary score of those.
There was no significant difference between the treat-
ments groups: most patients in both treatment groups
rated the results as ‘excellent’ to ‘good’ (72.1% in the
Nervoheel N group versus 73.7% in the lorazepam
group; P=0.84 for the between-treatment comparison;
Fig. 4).
Tolerability
Both treatments were well tolerated, with very few
adverse events and very good self-assessed tolerability
ratings by the patients. One patient in each group
experienced an adverse event (metallic taste with
Nervoheel N; drowsiness with lorazepam), both of
which were considered unlikely to be treatment related.
The overall patient-assessed tolerability profile was
significantly more favorable for Nervoheel N: 81.9%
of patients rated tolerability as ‘excellent’ compared with
45.5% in the lorazepam group (P<0,001 for the
between-treatment comparison; Fig. 5).
Compliance rates were high with both treatments and
differences between groups were not statistically signifi-
cant (P=0.35; Fig. 6). Compliance ratings of ‘excellent’
−1.5 −1 −0.5 0 0.5 1 1.5
Non-inferiority
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Sleep disturbances
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Lack of concentration
Sum of symptom scores
Favours lorazepam Favours Nervoheel
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Figure 3. Differences ( 95% confidence intervals) between the
treatment groups in change from baseline to last observation for all
individual variables and the sum of all variables. The border for non-
inferiority for Nervoheel N compared with lorazepam for the individual
variables (0.3) is marked by a dotted line. For the sum of all scores,
the non-inferiority was 3.0 and is not drawn to scale in the figure.
−8 −7 −6 −5 −4 −3 −2 −10
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Lorazepam
Intermediate
examination
Final
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Change from baseline (units)
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Figure 2. Change from baseline ( 95% confidence intervals) in sum of
symptom scores for the Nervoheel N and lorazepam groups,
respectively, at the intermediate and the final examinations.
Figure 4. Overall therapeutic results at the end of the study in the two
treatment groups. The difference between the groups was not
statistically significant.
Figure 5. Tolerability scores in the two treatment groups. The difference
between the groups was statistically significant.
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Nervoheel N group and the lorazepam group.
Discussion
The results of this open-label study indicate that
the homotoxicological preparation Nervoheel N offers
symptomatic relief from a variety of manifestations
summarized under the label ‘mild nervous disorders’:
aches, palpitations, indigestion, lack of appetite, mild
sexual dysfunction, fatigue, listlessness, sleep distur-
bances, restlessness, or lack of concentration. For these
conditions, Nervoheel might be a better-tolerated alter-
native to benzodiazepines, here represented by loraze-
pam. In our non-inferiority analysis, the degrees of
improvements were highly similar across the board for
the 11 different variables assessed, and non-inferiority of
Nervoheel N could be shown for all variables as well as
their summary score. The study is the first attempt to
evaluate the effectiveness of Nervoheel in a clinical
setting.
Although the results are from a preliminary, open-label
investigation assessing treatment effectiveness on a wide
variety of symptoms, the results are promising, as there is a
great need for a wider range of treatment options for
nervous disorders such as insomnia, anxiety and burnout
syndrome. The use of CAM practices is widespread for
nervous conditions and there is evidence that certain
flavonoid-rich herbal remedies may enhance the anxiolytic
and sedative properties of natural agonists of the benzo-
diazepine receptor. Extracts of the flavonoid-rich plant
Turnera aphrodisiaca Ward have a wide use in homeopathic
practices and were recently reported to exhibit anxiolytic
properties in a controlled mouse model, at the high
dilutions used in homeopathic practice (4). The American
Pomo people used Iris sp. root, also a flavonoid-rich
species, to accelerate the birthing process (15). The
anxiolytic properties of one or several of the constituents
of Nervoheel warrant further study. Both homeopathy
and the Nervoheel component, valerianate, are categorized
as evidence-level II (‘Evidence obtained from at least
one properly designed randomized controlled trial’) (16).
The greatest improvement with Nervoheel was observed
between the start of therapy and the intermediate
examination, which might be indicative of a ceiling
effect or adaptation to treatment, although the treatment
benefits effects remained throughout the study period.
To investigate this phenomenon further would require a
study with a washout period followed by a resumption of
therapy, which was not part of the current design.
There are limitations to the study. The entry criteria
for mild nervous disorders were defined fairly vaguely,
which corresponds to the variety of conditions encoun-
tered in routine clinical practice. Nervous disorders of
lesser severity are difficult to characterize with certainty
and there is an obvious subjective component involved
in the assessment. The problem of subjectivity is difficult
to assess, as in contrast to, e.g. depression, there are
no standardized rating scales for mild nervous disorders.
The study design left the evaluations largely to the
physicians’ discretion. This reflects everyday CAM use
more closely than a micro-managed evaluation system,
but also leaves greater scope for physician bias. As there
was no placebo control, the degree of possible regression
to the mean could not be assessed. The relatively large
number of patients in the study and the fact that
practices used both CAM and conventional approaches
to medicine are arguments for consistency of the
evaluations between individual patients and between
different study centers. Although there is no guarantee
that certain centers may have used slightly different
thresholds for their assessments of severity of symptoms,
the influence such differences would be expected to be
similar for patients in both treatments groups from
individual centers and thus not influence the comparison
of effects between the treatments groups.
Physical and psychological causes of nervous com-
plaints are often difficult to separate. This indicates
that a closer patient–practitioner relationship might
benefit the patient outside of benefits derived from
the pharmacological efficacy of the prescribed medica-
tion. Indeed, the relationship between patient and
practitioner in complementary medicine seems to be on
average closer and more mutually respectful than that
between conventional practitioners and patients (2).
In the current study, it is unlikely that the results were
more than marginally biased by differences in relation-
ships. The participating centers were chosen from
practices offering both CAM and conventional medicine
and there are no reasons to believe practitioners change
their behavior according to what they prescribe to
different patients. The point could also be made that
any beneficial psychological influences should be counted
as an argument in favor of CAM rather than as a
criticism.
Figure 6. Compliance scores in the two treatment groups. The difference
between the groups was not statistically significant.
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tional design as opposed to the ‘gold standard’ of
randomized, controlled clinical trials. However, both
observational and randomized studies yield valuable
information related to the benefit and disadvantages
with therapies (17–19). A typical feature of non-
randomized studies are differences at baseline between
treatment groups. In the current study, patients on
lorazepam were on average older and more likely to be
male, to smoke and to use alcohol or coffee regularly,
than patients in the Nervoheel N group. Propensity score
analysis was used to adjust for these differences, but
some residual bias may be present. The inclusion of one
patient aged 11 in the study population despite the
age restrictions in the enrollment criteria is illustrative of
the differences between observational studies, where the
physicians are less stringently monitored and randomized,
than in controlled trials.
The slightly larger number of patients in the Nervoheel
group might indicate some enrollment bias, but whether
such bias would favor one group over the other is
unclear. Observational studies typically include a wider
range of patient types than randomized trials, as the
inclusion and exclusion criteria are broader in the former
case. Given the extremely wide range of patients types
and symptoms that fall under the term ‘mild nervous
disorders’, a different study design would in all likelihood
have failed to enroll a large percentage of the kinds of
patients treated for these conditions, whether with
conventional or with CAM practices. Such an exclusion
would have limited the relevance of the investigation to
routine clinical practice by restricting the patient types
to which the results could be applied in everyday care.
Thus, the design sacrificed stringency for optimal
inclusiveness. The same argument can be raised against
the lack of standardized doses. Although most patients
received the recommended dosages of the respective
medications, there were no stipulation of doses in the
protocol. On the one hand, this restricted the stringency
of the effectiveness analysis, but on the other hand,
the outcomes reflect the effects of therapies as used in
daily practice rather than under the conditions of
controlled clinical trials.
One group of patients may have been missed: those
resorting to self-medication without seeking physicians’
advice. It would be interesting to attempt to address
the potential of Nervoheel N to help these patients, but
as both lorazepam and Nervoheel N are available by
prescription only, this group falls outside the scope of the
current investigation.
The boundaries of the non-inferiority analysis are
necessarily somewhat arbitrary, as no study has defined
what level of differences between therapies is clinically
relevant to patients for the complaints studied. However,
given the very small differences between treatment effects
in the two groups for all variables studied, there appears
to be no reason to think that the criteria for non-
inferiority were set too generously.
Lorazepam and other benzodiazepines are frequently
used to treat states such as generalized anxiety disorder
and have a well-demonstrated effect in randomized
clinical trials as well as in practice to reduce disability.
There seems to be little difference between members of
the class (20,21). It is unclear how far the non-inferiority
of the effectiveness of the homeopathic preparation in the
setting of the current study can be extrapolated to that of
benzodiazepines in randomized trials.
Good tolerability is a common characteristic of many
CAM medications and may be one reason for their
growing popularity as a reaction to perceived limitations
of conventional treatments (22). A significantly greater
proportion of patients rated their treatment as ‘excel-
lently’ tolerated in the Nervoheel N group than in the
lorazepam group. In this context, the greater average age
in the lorazepam group indicates that physicians pre-
scribe benzodiazepines to this age group despite contra-
indications in older people (7). The observed benefits and
good tolerability with Nervoheel might be particularly
interesting for this age group, although no Nervoheel
studies have been aimed specifically at the elderly.
The current study population was too small to allow
for meaningful subgroup analyses, but in a larger
population it would have been very interesting to analyze
the effects of the therapies in different age groups.
The ongoing controversies over safety of drugs such as
cerivastatin and rofecoxib have shown the limits of the
extent to which patients are willing to accept side effects,
whether immediate adverse effects or long-term risk for
complications, from drugs. The greatest concerns with
benzodiazepines regard their long-term use (23) and this
aspect of therapy was not addressed in the current 4-week
study, which did not report any dependency-related side
effects from lorazepam. However, although there is a
relationship between treatment duration and the risk for
dependence (8), physical and psychological dependence
with benzodiazepines can occur with the usual prescribed
doses and with short-term use (24–26). No such concerns
have been raised regarding CAM preparations such as
Nervoheel N.
In summary, this observational study indicates that,
in patients who opt for a homeopathic treatment regimen
for the short-term relief of mild complaints of nervous
origin, the effects of Nervoheel N are non-inferior to
those of the benzodiazepine, lorazepam. In addition,
the tolerability of Nervoheel N was rated as ‘excellent’ by
significantly more patients than that of lorazepam for the
4-week duration of the trial.
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